Therefore, it would be of interest whether discontinuation and exchange of therapy with ACE inhibitors (e.g., by calcium channel blockers) in AML patients who are at risk of suffering from sepsis is recommendable. The gene discussed is ACE; the disease is acute myeloid leukemia.